DFIB Cardiac Science (MM)

China Health Authority Grants Cardiac Science Approval to Sell Its Latest Line of Powerheart(R) AEDs Approved Products Include Powerheart and GE-Branded AEDs and Powerheart CRM Bedside Therapy Monitor IRVINE, Calif., June 28 /PRNewswire-FirstCall/ -- Cardiac Science Inc. (NASDAQ:DFIB) announced today that it has received regulatory approval from the People's Republic of China State Food and Drug Administration (SFDA) to sell its latest line of automatic external defibrillators (AEDs), including its Powerheart(R) brand public-access AEDs and the Powerheart(R) CRM(R), a unique bedside monitor that automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. The SFDA action provides clearance for Cardiac Science to begin shipments of its G3 series AEDs into China under its Powerheart and FirstSave(R) brands as well as under GE Healthcare's Responder(R) brand name which Cardiac Science manufactures on a private label basis for GE. Cardiac Science branded AEDs operate in the Chinese language and are sold through its local Chinese distribution partners. The GE Responder brand AEDs are marketed in China by GE Healthcare. Initially, AEDs are expected to be deployed principally in medical and emergency rescue settings and used by hospitals, physicians and paramedics on fire vehicles and ambulances. Historically, as new markets have developed, medical and first responder segments have been the first to deploy AEDs, followed by more widespread adoption for installation in government institutions, transportation, corporations, and other public places where citizens congregate. More than 100 Powerheart CRMs are currently in use in Chinese hospitals. Cardiac Science has gained a solid market share position in emerging AED markets around the world with international sales now accounting for approximately 40 percent of the Company's revenue said Chairman and Chief Executive Officer Raymond W. Cohen. "People all over the world are recognizing that AEDs offer an effective and inexpensive way to protect citizens against sudden cardiac arrest," Cohen said. "While the U.S. market continues to lead the way in the awareness and adoption of AEDs we believe the international market now accounts for over 20 percent of worldwide AED sales. China, which represents a large potential market for us, joins an extensive list of countries where our latest generation Powerheart AED G3 line is approved for sale including other Asia/Pacific countries like South Korea, Thailand, New Zealand and Australia and dozens of countries in Europe, South America and the Middle East. We plan to pursue our business aggressively in these countries and take advantage of the opportunities these regulatory approvals present us." About Cardiac Science Cardiac Science develops manufactures and markets a complete line of Powerheart(R) brand, automatic public-access defibrillators, commonly known as AEDs, and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The Company makes the Powerheart(R) CRM(R), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Nihon Kohden Corporation (Japan), Quinton Cardiology Systems and GE Healthcare. For more information please visit http://www.cardiacscience.com/ or call 1.949.797.3800. This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, from time to time the company, or its representatives, have made or may make forward looking statements orally or in writing. The words "estimate," "potential," "intended," "expect," "anticipate," "believe," and similar expressions or words are intended to identify forward looking statements. Such forward-looking statements include, but are not limited to, the possibility that the Regulatory Approval in China for its AEDs and CRMs will generate revenue for Cardiac Science from its distributors or GE Healthcare. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the Company's Form 10-K for the year ended December 31, 2004, and other documents filed by the Company with the Securities and Exchange Commission. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements. The Company does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. Contact: Rene Caron (Investors) Michael D. Gioffredi Len Hall (Media) Chief Marketing Officer Allen & Caron Inc. Cardiac Science, Inc. (949) 474-4300 (949) 797-3800 DATASOURCE: Cardiac Science, Inc. CONTACT: investors, Rene Caron, , or media, Len Hall, , both of Allen & Caron Inc., for Cardiac Science, Inc., +1-949-474-4300; Michael D. Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright